Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Gastroenterology

Journal Scan / Research · August 09, 2020

Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in IBD Patients Treated With Vedolizumab or Ustekinumab

Clinical Gastroenterology and Hepatology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Clinical Gastroenterology and Hepatology
Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients With Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab
Clin. Gastroenterol. Hepatol. 2020 Jul 12;[EPub Ahead of Print], A Hu, PG Kotze, A Burgevin, W Tan, A Jess, PS Li, K Kroeker, B Halloran, R Panaccione, L Peyrin-Biroulet, C Ma, AN Ananthakrishnan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading